Aquestive Therapeutics AQST
NASDAQ AQST
$4.66 +0.16 (+3.67%)
At close: Aug 21, 2026 · 4:00 PM EDT

Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025)

Aquestive Therapeutics (AQST) posted quarterly Capital Leases of $122000.0 for Q3 2025, down 20.26% year-over-year from $153000.0 in Q3 2024, and down 6.15% quarter-over-quarter from $130000.0 in Q2 2025.

Aquestive Therapeutics (AQST) Capital Leases (2023 - 2025) Analysis & Trends

Aquestive Therapeutics' Capital Leases history runs 3 years deep, the most recent figure standing at $122000.0 for Q3 2025.

  • In Q3 2025, Capital Leases fell 20.26% year-over-year to $122000.0; the TTM figure through Sep 2025 stood at $122000.0 (down 20.26% YoY), while the FY2024 annual figure was $146000.0, down 15.61% from the prior year.
  • Capital Leases for Q3 2025 stood at $122000.0, down from $130000.0 in the prior quarter.
  • The five-year high for Capital Leases was $173000.0 in Q4 2023, with the low at $122000.0 in Q3 2025.
  • The 3-year median for Capital Leases is $149500.0 (2024), against an average of $148625.0.
  • The sharpest annual moves came in 2024 and 2025: Capital Leases fell 15.61% in 2024, then fell 20.26% in 2025.
  • Aquestive Therapeutics' Capital Leases stood at $173000.0 in 2023, then decreased by 15.61% to $146000.0 in 2024, then slipped by 16.44% to $122000.0 in 2025.
  • Business Quant data shows AQST's Capital Leases at $122000.0 in Q3 2025, $130000.0 in Q2 2025, and $138000.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 44.51 Bn 43.55 Bn -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn -
10 Aquestive Therapeutics 583.72 Mn 583.72 Mn 9.80 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 122,000.00
Jun 30, 2025 130,000.00
Mar 31, 2025 138,000.00
Dec 31, 2024 146,000.00
Sep 30, 2024 153,000.00
Jun 30, 2024 160,000.00
Mar 31, 2024 167,000.00
Dec 31, 2023 173,000.00